Clinical use of dendritic cells for cancer therapy

Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).

Intratumoral vaccination with activated allogeneic dendritic cells in patients with newly diganosed metastatic renal cell carcinoma (mRCC).

Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.

Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.

A feasibility and safety study of vaccination with poly-ICLC and peptide-pulsed dendritic cells in patients with metastatic, locally advanced unresectable, or recurrent pancreatic adenocarcinoma.

Dendritic cell immunotherapy for glioblastoma

Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells

Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients